Birgit Spiess
Overview
Explore the profile of Birgit Spiess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
939
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kockerols C, Valk P, Janssen J, Hogenbirk P, Cornelissen J, Saussele S, et al.
Eur J Haematol
. 2024 Jul;
113(5):606-613.
PMID: 38994654
Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth...
2.
Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, et al.
Leukemia
. 2023 Dec;
38(2):318-325.
PMID: 38129513
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that reflect...
3.
Spiess B, Kleiner H, Tarnopolscaia I, Naumann N, Fabarius A, Hofmann W, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568730
Reverse transcriptases (RT) are essential tools in fusion transcript monitoring in chronic myeloid leukemia (CML). The RT type and cDNA priming method may impair the stoichiometry of cDNA synthesis, thereby...
4.
Christiani E, Naumann N, Weiss C, Spiess B, Kleiner H, Fabarius A, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174118
The achievement of major molecular response (MMR, ≤ 0.1% IS) within the first year of treatment with tyrosine kinase inhibitors (TKI) is a milestone in the therapeutic management of patients...
5.
Naumann N, Bross-Bach U, Seifarth W, Fabarius A, Hofmann W, Saussele S, et al.
EJHaem
. 2022 Dec;
3(4):1339-1342.
PMID: 36467807
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) of transcript level is an essential part of routine disease monitoring in patients with chronic myeloid leukemia. One patient sample (e13a2 transcript detected...
6.
Kohl V, Drews O, Costina V, Bierbaum M, Jawhar A, Roehl H, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34072546
Non-targeted effects (NTE) of ionizing radiation may initiate myeloid neoplasms (MN). Here, protein mediators (I) in irradiated human mesenchymal stromal cells (MSC) as the NTE source, (II) in MSC conditioned...
7.
Hoenigl M, Salmanton-Garcia J, Walsh T, Nucci M, Neoh C, Jenks J, et al.
Lancet Infect Dis
. 2021 Feb;
21(8):e246-e257.
PMID: 33606997
With increasing numbers of patients needing intensive care or who are immunosuppressed, infections caused by moulds other than Aspergillus spp or Mucorales are increasing. Although antifungal prophylaxis has shown effectiveness...
8.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al.
Leukemia
. 2020 Sep;
34(10):2823.
PMID: 32913312
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
9.
Jenks J, Prattes J, Frank J, Spiess B, Mehta S, Boch T, et al.
Clin Infect Dis
. 2020 Sep;
73(7):e1737-e1744.
PMID: 32866234
Background: The Aspergillus Galactomannan Lateral Flow Assay (LFA) is a rapid test for the diagnosis of invasive aspergillosis (IA) that has been almost exclusively evaluated in patients with hematologic malignancies....
10.
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al.
Leukemia
. 2020 May;
34(8):2074-2086.
PMID: 32382082
Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change...